EQS-News: Biotest AG
/ Key word(s): Miscellaneous
PRESS RELEASE
Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care
Medical Director Tanja Engelen gave a tour of the plasma donation centre and highlighted the paperless donation and the importance of plasma donation for medical care. "Plasma donations save lives and are urgently needed. I would like to personally thank the many donors who are willing to make a contribution to the care of seriously ill patients for their commitment," emphasised Prof Dr Karl Lauterbach in the donation room and also thanked the employees and management for their contribution to healthcare. The situation is serious, as supplies in Germany are becoming increasingly scarce and demand is constantly rising. Worrying supply bottlenecks of preparations due to plasma shortages mean disaster for many patients: they have to fear for their vital medicines. In the European Union, for example, a shortfall of 22% in plasma collection has been forecast for 2021. This corresponds to a shortfall of around 2 million litres of plasma for the supply of plasma preparations. "Germany is a good example of cooperation between public organisations and private companies in order to guarantee the nationwide supply of plasma. At European level, better protection of patients and donors will be regulated in future by the EU SoHO (Substances of Human Origin) Regulation, thus creating standardised competitive conditions," said Peter Janssen, CEO of Biotest AG. The collected plasma is processed exclusively in Germany at Biotest AG in Dreieich. Regular audits in Germany ensure that the high legal and internal quality and safety requirements are met.
About human blood plasma Human blood plasma is a raw material used to produce plasma derived products, which are used to treat various illnesses of the immune system, the blood system, as well as in emergency medicine. Biotest ranks as one of the world's sixth largest plasma protein product manufacturing groups. Biotest is one of the world's six largest manufacturers of plasma protein products.
About Biotest Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com).
IR contact Dr Monika Baumann (Buttkereit) Phone: +49-6103-801-4406
PR contact Dirk Neumüller Phone: +49-6103-801-269
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Preference shares: securities’ ID No. 522723; ISIN DE0005227235 Listing: Frankfurt (Prime Standard) Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate Disclaimer
28.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Biotest AG |
Landsteinerstraße 5 | |
63303 Dreieich | |
Germany | |
Phone: | 0 61 03 - 8 01-0 |
Fax: | 0 61 03 - 8 01-150 |
E-mail: | ir@biotest.com |
Internet: | www.biotest.de |
ISIN: | DE0005227235, DE0005227201 |
WKN: | 522723, 522720 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1846715 |
End of News | EQS News Service |
|
1846715 28.02.2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.